A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Clicks: 280
ID: 274346
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov numb …
Reference Key
dr2020thea Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Boulware DR;Pullen MF;Bangdiwala AS;Pastick KA;Lofgren SM;Okafor EC;Skipper CP;Nascene AA;Nicol MR;Abassi M;Engen NW;Cheng MP;LaBar D;Lother SA;MacKenzie LJ;Drobot G;Marten N;Zarychanski R;Kelly LE;Schwartz IS;McDonald EG;Rajasingham R;Lee TC;Hullsiek KH;;
Journal The New England journal of medicine
Year 2020
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/32492293
Keywords
canada National Center for Biotechnology Information NCBI NLM MEDLINE covid-19 sars-cov-2 humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult female male N.I.H. Extramural middle aged Randomized Controlled Trial Double-Blind Method Multicenter Study United States pneumonia betacoronavirus occupational exposure coronavirus infections / prevention & control* pandemics / prevention & control* viral / prevention & control* treatment failure hydroxychloroquine / therapeutic use* pmid:32492293 pmc7289276 doi:10.1056/nejmoa2016638 david r boulware matthew f pullen kathy h hullsiek hydroxychloroquine / adverse effects inhalation exposure post-exposure prophylaxis*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.